Masson Kristina — SEC Form 4 filings
SEC reporting owner CIK 1950501. 25 Form 4 filings on record with FilingPulse; latest filed 2026-08-27.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2024-02-16 to 2026-08-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 49,000 shares, $82,124 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 15,749 shares, $34,412 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: purchase of 49,000 shares @ $1.68 ($82,124) in Acrivon Therapeutics, Inc., filed 2026-01-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | EVP - Business Operations, Director | 25 | 1 leg · 49,000 sh · $82,124 | 3 legs · 15,749 sh · $34,412 | 33 |
Form 4 filings — Masson Kristina
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-27 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Sale (S): 14,036 @ $2.21 | EDGAR |
| 2026-08-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Sale (S): 1,229 @ $2.01 · Sale (S): 484 @ $2.01 | EDGAR |
| 2026-05-26 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 13,729 @ $1.79 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Grant/award (A): 180,095 @ $0 · Grant/award (A): 72,706 @ $0 | EDGAR |
| 2026-05-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 1,253 @ $1.92 · Tax withholding (F): 490 @ $1.92 | EDGAR |
| 2026-03-03 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Grant/award (A): 417,210 (derivative) @ $0 · Grant/award (A): 185,495 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 14,265 @ $1.53 | EDGAR |
| 2026-02-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 1,302 @ $1.63 · Tax withholding (F): 579 @ $1.63 | EDGAR |
| 2026-01-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Purchase (P): 49,000 @ $1.68 | EDGAR |
| 2025-11-25 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 19,904 @ $2.30 | EDGAR |
| 2025-11-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 59,765 @ $2.24 · Tax withholding (F): 490 @ $2.24 | EDGAR |
| 2025-08-25 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 19,905 @ $1.32 | EDGAR |
| 2025-08-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 59,766 @ $1.39 · Tax withholding (F): 490 @ $1.39 | EDGAR |
| 2025-05-23 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 19,904 @ $1.15 | EDGAR |
| 2025-05-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 59,766 @ $1.14 · Tax withholding (F): 491 @ $1.14 | EDGAR |
| 2025-03-04 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Grant/award (A): 390,390 (derivative) @ $0 · Grant/award (A): 140,540 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 19,904 @ $5.54 | EDGAR |
| 2025-02-19 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 37,152 @ $5.42 · Tax withholding (F): 579 @ $5.42 | EDGAR |
| 2024-11-27 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Grant/award (A): 225,226 (derivative) @ $0 · Grant/award (A): 90,090 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 19,910 @ $6.44 | EDGAR |
| 2024-11-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 59,766 @ $7.92 · Tax withholding (F): 490 @ $7.92 | EDGAR |
| 2024-08-23 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with Blume-Jensen Peter | Tax withholding (F): 79,616 @ $9.19 | EDGAR |
| 2024-08-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 490 @ $7.02 | EDGAR |
| 2024-05-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 490 @ $8.36 | EDGAR |
| 2024-02-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 579 @ $3.40 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1950501 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →